Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1

Conditions

Sarcoma 2Small Cell Lung Carcinoma 1Recurrence 1Prostatic Neoplasms 1Leiomyosarcoma 1Ichthyosis, X-Linked 1Glioblastoma 1Carcinoma, Non-Small-Cell Lung 1

Interventions

Etoposide 30Carboplatin 29atezolizumab 17durvalumab 16Cisplatin 14Topotecan 11Specimen Handling 9PM 01183 9Magnetic Resonance Spectroscopy 7pembrolizumab 6olaparib 5berzosertib 4anlotinib 4Radiotherapy 4Nivolumab 4Irinotecan 4Drug Therapy 4tremelimumab 3toripalimab 3tislelizumab 3Paclitaxel 3Injections 3Docetaxel 3Biopsy 3Bevacizumab 3AMG 757 3sacituzumab govitecan 2monalizumab 2cabozantinib 2Temozolomide 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Small Cell Lung Carcinoma × ADI PEG20 × 90 days × Clear all
NCT05616624 2026-04-15

ADI-PEG 20 in Combination With Gemcitabine and Docetaxel After Progression on Frontline Therapy in Non-small Cell and Small Cell Lung Cancers

Washington University School of Medicine

Phase 1/2 Active not recruiting
31 enrolled
Thoracic

Carcinoma, Non-Small-Cell Lung, Small Cell Lung Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡